ADA 2019—The artificial pancreas is ready for its clinical closeup


  • Emily Willingham, PhD
  • Conference Reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Artificial pancreas systems are safe and effective for insulin delivery and glycemic control, including children, according to a pair of studies presented at the American Diabetes Association conference.

Why this matters

  • The technology appears to be on the cusp of approval.

Key results

  • In 1 study, 6-month outcomes showed that a closed-loop control system bested a sensor-augmented pump therapy for time-in-target range by 11%.
    • Closed-loop control also reduced HbA1c by 0.33% more and mean glucose by 13.
    • It was also tied to a decrease in hyperglycemia
    • 100% of participants (ages 14-71 years) completed the trial and were still using the system at 6 months.
    • Benefit seen in first month and sustained.
  • In a French study comparing 24-hour use of a closed-loop system vs nighttime use only, the 30 children (ages 6-12 years) with type 1 diabetes in the trial had 80% time-in-range with nighttime use.
    • These findings are interim but suggest limited risk for nighttime hypoglycemia.

Limitations

  • Data were presented without peer review at a conference and are preliminary for study 2.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit